News

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.
On Thursday, the U.S. Food and Drug Administration (FDA) began to alert patients, caregivers and healthcare professionals about Pfizer’s voluntary withdrawal of OXBRYTA. The withdrawal comes ...
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer PFE0.69%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...
Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® for the treatment of sickle cell disease at this time, in all markets where it is approved. Pfizer is also ...
Pfizer has withdrawn Oxbryta from global markets and halted all clinical trials, citing safety concerns following clinical data that raised issues about fatal complications in sickle cell disease ...
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at ...